CoChat

Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Viral vector-based gene therapies (GTx) have received significant attention in the recent years and the number of ongoing GTx clinical trials is increasing. A platform of choice for many of these studies is adeno-associated virus (AAV). All humans may be exposed to natural AAV infections and could mount an immune response against the virus. Consequently, there can be a high prevalence of pre-existing anti-AAV immunity. This presents a potential limitation for AAV-based GTx due to the potential for AAV-specific antibodies to reduce the efficacy of the GTx. Therefore, appropriate assessment of potential subjects enrolled in these studies should include evaluation for the presence and degree of anti-AAV immunity, including anti-AAV neutralizing antibodies (NAb). Recommendations for the development and validation of cell-based anti-AAV NAb detection methods, including considerations related to selection of appropriate cell line, surrogate vector/reporter gene, assay matrix and controls, and methodologies for calculating assay cut-point are discussed herein. General recommendations for the key assay validation parameters are provided as well as considerations for the development of NAb diagnostic tests. This manuscript is produced by a group of scientists involved in GTx therapeutic development representing various companies. It is our intent to provide recommendations and guidance to industrial and academic laboratories working on viral vector based GTx modalities with the goal of achieving a more consistent approach to anti-AAV NAb assessment.

Overview

Integrity signals

Registry

Crossref · 10.1208/s12248-019-0403-1

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 58 references

Cited by

See all 57

Metadata

Authors
Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S.
Affiliations
  • Pfizer (United States) (US)
  • Regenxbio (United States) (US)
  • Bluebird Bio (United States) (US)
  • Precision for Medicine (United States) (US)
  • BioMarin (United States) (US)
  • Alzheimer's Drug Discovery Foundation (US)
Corresponding author
Gorovits, Boris
Venue
The AAPS Journal
Published
2020-01-06
Volume
22
Issue
2
Pages
24-24
ISSN
1550-7416 (ISSN-L)
OpenAlex
W2998517578
Cited by
57
References
58
Citations by year
2026: 5 · 2025: 8 · 2024: 10 · 2023: 16 · 2022: 6 · 2021: 8 · 2020: 2
FWCI
1.15
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The AAPS Journal (publishedVersion)
  • PubMed (publishedVersion)
  • The Novartis Repository (Novartis) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus, viral vector gene therapy, assay validation
MeSH terms
Dependovirus, Antibodies, Viral, Biological Assay, Cell Line, Genetic Vectors, Humans, Immunologic Tests, Predictive Value of Tests, Reproducibility of Results, Genetic Therapy, Genes, Reporter, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. https://app.cochat.ai/papers/10.1208/s12248-019-0403-1
The paper
Gorovits, B., Fiscella, M., Havert, M., Koren, E., Long, B., Milton, M., & Purushothama, S. (2020). Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. The AAPS Journal. https://doi.org/10.1208/s12248-019-0403-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.